NET LOSS 71.90 %
AVG 2.72 (CURRENT VALUE 0.765)
ST
| ID |
stock |
number |
price |
Field1 |
plan |
current price |
share amount |
current lost price |
net loss |
fill amount |
filled price |
fill total |
grand total |
grand share |
grand avg |
GAP |
| 5 |
CRDL |
$92.00 |
$2.72 |
$250.24 |
|
$0.67 |
$92.00 |
$61.64 |
($188.60) |
$0.00 |
$0.00 |
$0.00 |
$250.24 |
$92.00 |
$2.72 |
|
REPURCHASE
ST
| ID |
stock |
number |
price |
Field1 |
plan |
current price |
share amount |
current lost price |
net loss |
fill amount |
filled price |
fill total |
grand total |
grand share |
grand avg |
GAP |
| 6 |
CRDL |
$101.00 |
$0.77 |
$77.27 |
|
$0.78 |
$101.00 |
$78.29 |
$1.02 |
$0.00 |
$0.00 |
$0.00 |
$77.27 |
$101.00 |
$0.77 |
|
ST
| ID |
stock |
number |
price |
Field1 |
plan |
current price |
share amount |
current lost price |
net loss |
fill amount |
filled price |
fill total |
grand total |
grand share |
grand avg |
GAP |
| 6 |
CRDL |
$101.00 |
$0.77 |
$77.27 |
|
$0.77 |
$100.00 |
$76.50 |
($0.77) |
$0.00 |
$0.00 |
$0.00 |
$77.27 |
$101.00 |
$0.77 |
|
Cardiol Therapeutics Inc. (NASDAQ: CRDL) is a clinical-stage life sciences company specializing in anti-inflammatory and anti-fibrotic therapies for heart diseases.
Cardiol Therapeutics Inc (CRDL)
$1.37
+$0.08(+6.64%)Today
$1.47+$0.10(+7.30%)Pre-Market
Financial Overview:
Revenue: For the fiscal year ending December 31, 2023, Cardiol Therapeutics reported minimal revenue, consistent with its status as a clinical-stage company.
Net Loss: The company recorded a net loss of approximately $20.84 million for the same period, reflecting ongoing research and development expenditures.
Cash Position: As of December 31, 2023, the company held cash and short-term investments totaling approximately $34.93 million, providing a financial runway for its clinical programs.
Analyst Ratings and Price Targets:
Consensus Rating: Cardiol Therapeutics has received a consensus rating of "Buy" from multiple analysts, indicating optimism about the company's prospects.
Price Targets: The average twelve-month price target is $8.75, with estimates ranging from $7.89 to $10.00, suggesting a significant potential upside from the current share price.
Recent Analyst Activity: On December 18, 2024, HC Wainwright reiterated a "Buy" rating with a $9.00 price target, reflecting confidence in the company's strategic direction.
Recent Developments:
Clinical Trials:
The company has completed patient enrollment in its Phase II
MAvERIC-Pilot study investigating CardiolRx™ for recurrent pericarditis, with topline results expected in Q2 2024.
Regulatory Designations: CardiolRx™ has been granted Orphan Drug Designation by the U.S. FDA for the treatment of pericarditis, potentially expediting its development and approval process.
Considerations for Investors:
While Cardiol Therapeutics shows promise with its innovative therapies and favorable analyst outlook, potential investors should be mindful of the inherent risks associated with clinical-stage biotech companies, including regulatory hurdles, clinical trial outcomes, and market competition.
It's advisable to conduct thorough due diligence and consider these factors when evaluating investment opportunities in the biotech sector.
No comments:
Post a Comment